Primary Breast Cancer Clinical Trial
Official title:
Neoadjuvant Chemotherapy With 3x Epirubicin/Docetaxel Followed by 3x Carboplatin/Docetaxel in Patients With Primary Breast Cancer
The purpose of this study is to optimize results in neoadjuvant chemotherapy of local advanced primary breast cancer. Therefore patients become first 3 cycles of Epirubicin/Docetaxel followed by 3x Carboplatin/Docetaxel.
Most of the women who are diagnosed with breast cancer are in the situation that an
operation is possible. Using a neoadjuvant therapy the rate of breast-conserving surgery can
be extended and tumor cell proliferation may be inhibited. Further the neoadjuvant
chemotherapy is an in-vivo-activity-test for the used drugs. Epirubicin, Docetaxel and
Carboplatin have shown antineoplastic activity against solid cancer alone and in
combination.
Using two different combinations of these three drugs, first 3 cycles Epirubicin/Docetaxel
and then changing to Carboplatin/Docetaxel for 3 further cycles it is assumed that the
results of the therapy will improve. Main criterion is the determination of pCR, second
criteria are the rate of breast-conserving surgery, tumor response and therapy-dependent
toxicities.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05923177 -
Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3
|
Phase 1 | |
| Completed |
NCT01033162 -
Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care
|
N/A | |
| Recruiting |
NCT03270007 -
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
|
Phase 4 | |
| Completed |
NCT04468113 -
Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy
|
||
| Recruiting |
NCT03711877 -
Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)
|
Phase 3 | |
| Active, not recruiting |
NCT01019616 -
Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy
|
Phase 3 | |
| Completed |
NCT01314833 -
Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy
|
Phase 3 | |
| Completed |
NCT04127019 -
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
|
Phase 3 | |
| Terminated |
NCT00172068 -
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
|
Phase 2 | |
| Completed |
NCT01049425 -
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT01840293 -
Breast Cancer Proteomics and Molecular Heterogeneity
|
||
| Completed |
NCT01779479 -
Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)
|
Phase 2 | |
| Completed |
NCT04277338 -
Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3
|
Phase 1 | |
| Recruiting |
NCT05445050 -
mULM to Support Breast Cancer Diagnosis and Therapy
|
N/A | |
| Completed |
NCT00793377 -
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
|
Phase 3 |